HTG2014-Section-Header-publications

Categories

Filter by Topics

ADCC Gene Alteration adolescents ALK Angiogenesis Apoptosis Autocrine Signaling Biology of neoplasia Biomarkers Bladder Cancer Blood Brain Breast Cancer Cardiovascular Disease CDKN2A mutation Cell Free Plasma Cells Chemokines Circulating miRNAs Colorectal cancer Comparison study Core Needle Biopsy COVID-19 Custom mRNA Cytokines Developmental Immunotherapy Developmental Therapeutics Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Efficacy EMT Epstein-Barr ERBB3 Esophageal Cancer Exosomes extracellular miRNAs Extracellular Vesicles Feasibility FFPE FGF Ligand Trap FGFR Follicular lymphoma Gene Expression Gene Expression Profiling Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors Head and Neck Cancer Heart HER-2 HER2- HLA-E Homing HPV HR+ HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System Immune Cells Immune Checkpoint Inhibitors Immune Response Immune System Immuno-Oncology Immunotherapy Integrins Kidney Liposarcoma Liquid Biopsy Liver liver tissue Lung Lupus Lymphocytes Lymphoma Melanoma Mesothelioma Microenvironment miRNA Molecular Characterization Mouse mRNA custom mTOR signaling Multiple Myeloma MYC Natural Killer Cells Neoantigens Novel Therapeutic Targets Oral Cancer Osteoarthritis PALLET PALOMA-2 Pancreas Pathway Analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-L1 PENELOPE-B PFAS PIK3CA mutation Plasma Platform Comparison Programmed cell death protein 1 Prostate Prostate Cancer qNPA qPCR Renal Cell Carcinoma Reproductive Reveal Rheumatoid Arthritis safety Sarcoma Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures Sinonasal Carcinoma Squamous cell carcinoma Sub-typing Therapeutic Response TMB Toxicity TP53 mutation Transplantation Treatment Outcome Treatment Stratification Tumor Biology Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Microenvironment tumor microenvironment Urine Urothelial carcinoma VEGFR Xenograft Tissue

2022

Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET

Cheang, M. et al., Abstract PD2-07: Impact of using cross-platform gene expression profiling technologies and computational methods for intrinsic breast cancer subtyping in PALOMA-2 and PALLET

View External Link

Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

Denkert, C., et al., Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib

View External Link

2021

Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery

Stratakis, N., et al., Associations between liver PFAS concentrations and plasma extracellular miRNAs in a cohort of adolescents undergoing bariatric surgery, Environemental Health Perspectives, https://ehp.niehs.nih.gov/doi/abs/10.1289/isee.2021.O-TO-140

View External Link

Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates

Kwak, M., et al., Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates,  J Transl Med 19, 371 (2021). https://doi.org/10.1186/s12967-021-03044-5

View External Link

Antigen-experienced CXCR5- CD19low B cells are plasmablast precursors expanded in SLE

Dorner, T.,  et al. Antigen-experienced CXCR5- CD19low B cells are  plasmablast precursors expanded in SLE.  medRxiv preprint May 27, 2021 https://doi.org/10.1101/2021.05.25.21257784doi

Download pdf 11.1MB

Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma.

Bustos, M. A., et al. Diagnostic ability of four cell-free miRNA signatures pre- and post-nephrectomy concordantly found in the tumor and blood from patients with renal cell carcinoma. J Clin Oncol 39, 2021 (suppl 15; abstr e16577); DOI: 10.1200/JCO.2021.39.15_suppl.e16577

View External Link

Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.

Denkert, C., et al. Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. J Clin Oncol 39, 2021 (suppl 15; abstr 519) DOI: 10.1200/JCO.2021.39.15_suppl.519

View External Link

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

Loibl, S., et al. Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 506) DOI: 10.1200/JCO.2021.39.15_suppl.506

View External Link

Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.

Marmé, F., et al. Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B. J Clin Oncol 39, 2021 (suppl 15; abstr 518). DOI 10.1200/JCO.2021.39.15_suppl.518

View External Link

Page last updated April 19, 2022